Cipla cash flow

Latest FY26

Cash from operations: ₹3,940cr−21.3% on FY25
Capital spending: ₹3,079cr+98.9% on FY25
Free cash flow: ₹861cr−75.1% on FY25
Cash from financing: −₹1,234cr−₹1,293 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	1,253	1,107	1,051	1,172
	—	0.0	0.0	0.0	−25.8
	—	54.4	62.0	89.9	110
	—	−229	−264	−220	−162
	—	−128	−235	−222	−20.7
	—	59.1	47.3	46.2	39.0
	—	−103	−13.9	−22.8	−56.2
	—	4.9	−2.0	4.7	137
	—	−384	−184	−86.6	−132
	—	0.0	0.0	195	0.0
	—	−642	−323	−61.9	111
	—	465	−802	−907	−652
	—	−701	0.0	0.0	0.0
	—	253	459	163	−18.2
	—	400	0.0	0.0	0.0
Cash from operating activities
	3,859	5,224	6,821	5,702	4,038
	—	303	−148	29.5	501
	—	5,526	6,673	5,731	4,540
	—	1,586	1,668	1,597	1,302
	—	3,940	5,005	4,134	3,238
Cash from investing activities
	—	1,599	1,162	1,098	841
	—	1,480	386	251	342
	—	23.6	24.9	34.2	29.6
	—	44.1	8.6	0.0	18.9
	—	17.4	17.8	6.0	0.0
	—	0.0	0.0	0.6	0.0
	—	15.6	30.6	42.0	187
	—	0.0	0.0	0.0	25.8
	—	111	205	301	0.0
	—	0.0	0.0	120	0.0
	—	0.0	26.8	8.7	0.0
	—	0.0	0.0	33.6	0.0
	—	223	260	208	114
	—	606	−2,156	−1,678	−1,207
	—	−2,326	−3,691	−2,988	−2,389
Cash from financing activities
	—	0.0	0.1	0.0	0.1
	—	188	12.0	0.0	0.0
	—	0.0	98.0	300	352
	—	108	80.2	77.0	134
	—	37.0	36.4	64.8	65.0
	—	1,292	1,050	686	404
	—	15.8	−40.4	−72.0	−4.3
	—	−1,234	−1,293	−1,200	−958
	—	380	21.1	−54.6	−109
	—	92.5	9.3	5.6	12.4
	—	473	30.3	−49.0	−96.8
	—	1,015	543	512	561
Reference items
	4,790	5,883	7,128	6,291	5,027
	17.0%	20.9%	25.9%	24.4%	22.1%
	861	861	3,457	2,785	2,055
	—	990	3,265	2,446	—
	₹10.65	₹10.65	₹42.79	₹34.47	₹25.44
	127.45×	—	—	—	—
	—	1.02×	0.95×	1.00×	1.14×
	—	1,586	1,668	1,597	1,302
	—	37.0	36.4	64.8	65.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

CIPLA₹1,358.00

Cipla Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA DRREDDY LUPIN APOLLOHOSP MAXHEALTH DIVISLAB TORNTPHARM ZYDUSLIFEMcap ₹1.10L Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	1,172.1	1,051.0	1,107.0	1,253.0	—
+ Impairment Loss / (Reversal)	-25.8	0.0	0.0	0.0	—
+ Finance Costs	109.5	89.9	62.0	54.4	—
+ Interest Income	-162.2	-219.6	-264.4	-228.6	—
+ Fair Value (Gains) / Losses	-20.7	-222.0	-234.6	-128.1	—
+ Share-based Payments	39.0	46.2	47.3	59.1	—
+ Unrealised FX (Gain) / Loss	-56.2	-22.8	-13.9	-103.3	—
+ Other Non-cash Items	136.7	4.7	-2.0	4.9	—
+ Other — Cash Effects are Investing / Financing	-131.9	-86.6	-183.8	-383.5	—
+ Other Reconciling Items	0.0	194.8	0.0	0.0	—
Changes in Working Capital
+ Inventories	110.8	-61.9	-322.5	-642.4	—
+ Trade Receivables — Current	-652.0	-907.0	-801.9	465.3	—
+ Other Current Assets	0.0	0.0	0.0	-701.2	—
+ Trade Payables — Current	-18.2	162.7	458.9	252.6	—
+ Other Current Liabilities	0.0	0.0	0.0	400.5	—
Cash from Operating Activities
Profit Before Tax (per I/S)	4,038.4	5,701.9	6,820.8	5,223.6	3,859.4
+ Total Adjustments (incl. Working Capital)	501.2	29.5	-147.7	302.6	—
Cash from Operations (pre-tax)	4,539.5	5,731.4	6,673.1	5,526.2	—
+ Income Taxes Paid	1,301.9	1,597.5	1,668.1	1,586.2	—
Cash from Operating Activities	3,237.7	4,133.9	5,005.0	3,940.0	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	840.5	1,098.3	1,162.2	1,599.3	—
+ Acq of Intangible Assets	342.4	251.1	386.0	1,480.0	—
+ Disp of Fixed Assets	29.6	34.2	24.9	23.6	—
+ Disp of Intangible Assets	18.9	0.0	8.6	44.1	—
+ Acq of Other Long-term Assets	0.0	6.0	17.8	17.4	—
+ Disp of Other Long-term Assets	0.0	0.6	0.0	0.0	—
+ Purchase of Investments (Equity / Debt)	186.9	42.0	30.6	15.6	—
+ Sale of Investments (Equity / Debt)	25.8	0.0	0.0	0.0	—
+ Acq of Subsidiaries / Businesses (net)	0.0	300.9	205.1	110.7	—
+ Disp of Subsidiaries / Businesses (net)	0.0	120.4	0.0	0.0	—
+ Loans & Advances Made	0.0	8.7	26.8	0.0	—
+ Government Grants Received	0.0	33.6	0.0	0.0	—
+ Interest Received — Investing	114.0	208.2	260.2	222.9	—
+ Other Inflows / (Outflows) — Investing	-1,206.9	-1,678.1	-2,156.2	606.3	—
Cash from Investing Activities	-2,388.5	-2,988.0	-3,691.1	-2,326.1	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.1	0.0	0.1	0.0	—
+ Proceeds from Borrowings	0.0	0.0	12.0	187.8	—
+ Repayment of Borrowings	351.9	300.5	98.0	0.0	—
+ Payment of Lease Liabilities	133.7	77.0	80.2	107.8	—
+ Interest Paid	65.0	64.8	36.4	37.0	—
+ Dividends Paid	403.5	686.2	1,049.8	1,292.4	—
+ Other Inflows / (Outflows) — Financing	-4.3	-72.0	-40.4	15.8	—
Cash from Financing Activities	-958.3	-1,200.4	-1,292.8	-1,233.7	—
Net Changes in Cash (pre-FX)	-109.2	-54.6	21.1	380.2	—
+ Effect of FX Rate Changes on Cash	12.4	5.6	9.3	92.5	—
Net Changes in Cash	-96.8	-49.0	30.3	472.7	—
Closing Cash	561.3	512.3	542.7	1,015.4	—
Reference Items
EBITDA	5,027.0	6,291.1	7,127.9	5,882.9	4,790.1
EBITDA Margin %	22.09	24.41	25.87	20.89	17.02
Free Cash Flow (CFO − Capex)	2,054.8	2,784.6	3,456.8	860.7	860.7
Free Cash Flow to Equity	—	2,446.4	3,265.5	989.6	—
Free Cash Flow per Basic Share	25.44	34.47	42.79	10.65	10.65
Price to Free Cash Flow	—	—	—	—	127.45
Cash Flow to Net Income	1.14	1.00	0.95	1.02	—
Cash Paid for Taxes	1,301.9	1,597.5	1,668.1	1,586.2	—
Cash Paid for Interest	65.0	64.8	36.4	37.0	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 146%.